Collegium Pharmaceutical vs Harmony Biosciences
COLL and HRMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COLL and HRMY compare
Harmony Biosciences is the larger company, worth 2.4 times as much as Collegium Pharmaceutical ($2.0B against $824M).
On earnings, Harmony Biosciences is cheaper: it trades at 11.1× trailing earnings, against 25.3× for Collegium Pharmaceutical.
Harmony Biosciences grew revenue faster over the last twelve months (19.8% versus 7.7% for Collegium Pharmaceutical).
Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.1% compared with 4.7% at Collegium Pharmaceutical.
Harmony Biosciences scores higher on the StockData Score (18 against 9 for Collegium Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COLL | HRMY |
|---|---|---|
| Size and price | ||
| Market cap | $824M | $2.0B |
| Share price | $25.32 | $33.76 |
| Change, 1 year | −46.5% | 0.66% |
| Change, 5 years | 34.3% | −12.9% |
| Beta (5Y) | 0.47 | 0.93 |
| Employees | 423 | 293 |
| StockData Score | ||
| Total score | 9 | 18 (better) |
| Valuation score | 2 | 6 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 25.3× | 11.1× (better) |
| P/S | 1.0× (better) | 2.0× |
| P/B | 2.8× | 1.8× (better) |
| EV/EBITDA | 5.5× (better) | 6.1× |
| P/FCF | 2.5× | – |
| FCF yield | 40.8% | – |
| Fair value | $44.42 | $56.70 |
| Margin of safety | 43.0% (better) | 40.5% |
| Growth | ||
| Revenue growth (TTM) | 7.7% | 19.8% (better) |
| Revenue growth, 5Y average | 20.3% | 40.3% (better) |
| Net income growth (TTM) | −34.7% | −3.8% (better) |
| EPS growth (TTM) | −37.9% | −4.7% (better) |
| EPS growth, 5Y average | 17.9% | – |
| Profitability | ||
| Gross margin | 59.0% | 74.0% (better) |
| Operating margin | 15.2% | 22.2% (better) |
| Net margin | 4.7% | 18.1% (better) |
| FCF margin | 41.3% | – |
| Return on equity | 13.4% | 18.7% (better) |
| Return on invested capital | 160% (better) | 43.1% |
| Financial health | ||
| Debt / equity | – | 0.14 |
| Net debt / EBITDA | – | −2.84 |
| Interest coverage | 1.6× | 17.0× (better) |
| Current ratio | 1.01 | 3.44 (better) |
| Altman Z-score | 0.81 | 4.90 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 121% | 93.0% |
| Held by insiders | 4.3% | 12.1% |
| Insider net buying, 12 months | −$4.4M (better) | −$5.8M |
| Short interest, % of float | 16.7% | 13.0% |
Go deeper
- COLL stock overview
- COLL income statement
- COLL valuation and score
- HRMY stock overview
- HRMY income statement
- HRMY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.